Efficacy And Adverse Metabolic Of Lurasidone Treating Schizophrenia: A Meta-analysis

Objective:Lurasidone is the type of atypical antipsychotics that approved by FDA at 2010,and it is widely used in psychiatric clinic.Although Lurasidone is effective,there is still lack of evidence of curative effect and adverse metabolic reactions in Evidence-based medicine.Based on the result of the Clinical randomized controlled trial about the Lurasidone in the treatment of schizophrenia in domestic and abroad,Through the method of Meta analysis,we could evaluate the curative effect and adverse metabolic reactions of Lurasidone in the treatment of schizophrenia objectively,and to provide the choose basis for the treatment of schizophrenia.Methods:Collect the clinical randomized controlled trial about the Lurasidone in the treatment of schizophrenia through the PUBMED?EMBASE?Cochrane Library?Elsevier,CNKI,CBM,VIP and WAN FANG database(Time: From the data setting up to December,2016).The collected literature was strictly screened according to the inclusion and exclusion criteria,for the screened research,quality was evaluated through the risk assessment tool based on Cochrane collaboration network and collected the relevant date,then used the statistical software RevMan5.2 to do the Meta-analysis,Switched effect model for the sensitivity analysis,Published the bias through the funnel plots analysis.Results:A total of 7 randomized controlled trials that met the inclusion criteria were included in this study,with a total sample size of 2615 people.From the randomized controlled trials between the Lurasidone and placebo,there were 5 items to provide the change of PANSS,CGI-S endpoint score and the change of weight compared to the baseline,3 items to provide a change in the value of the BMI endpoint compared to the baseline,1 item to provide a change of blood glucose and blood lipid.according to the result of Meta-analysis: compared with placebo,before and after treatment,the score of PANSS scale [MD=-5.60,95%CL(-8.69,-2.52),p =0.0004],thescore of CGI-S scale [MD=-0.31,95%CI(-0.50,-0.12),p =0.001],the weight changes[MD=0.47,95%CL(0.23,0.72),p =0.0002],the BMI changes[MD=0.23,95% CL(0.10,0.35),p =0.0003],all the Differences were statistically significant,it showed that Lurasidone had better effect than placebo in the treatment of schizophrenia,but caused the weight and BMI increasing easily.There were only one literature involved in the comparing between the Lurasidone and placebo,so in terms of blood glucose and blood lipid,Due to too little literature,Quantitative Meta-analysis should not be performed,only provide Descriptive analysis.It is lack of randomized controlled trials between the Lurasidone and other antipsychotics,so only provide descriptive analysis at the curative effect and adverse metabolic reactions.Conclusion:The efficacy of Lurasidone in the treatment of schizophrenia is definite,the same as other antipsychotics;Compared with other non classical antipsychotic drugs,Lurasidone has little effect on body weight and metabolic parameters.